St. Jude Children's Research Hospital;St. Jude Childrens Research Hospital
发明人:
Vignali, Dario A. A.,Woo, Seng-ryong,Delgoffe, Greg M.
申请号：
AU2018228501
公开号：
AU2018228501A1
申请日:
2018.09.10
申请国别(地区):
AU
年份:
2018
代理人:
摘要：
#$%^&*AU2018228501A120180927.pdf#####ABSTRACT The invention is directed to treatment of cancer, infections and various inflammatory and autoimmune conditions by affecting regulatory T cell stability and function via a Neuropilin-1 :Semaphorin axis. The present invention satisfies this and other needs by demonstrating that the regulatory T cell (Treg)-restricted neuropilin-1 (Nrp I) interacts with the cell surface ligand sema-phorin-4a (Sema4a) (e.g., on conventional T cells (Tconv), conventional dendritic cells (cDCs), and/or plasmacytoid dendritic cells (pDCs)) to potentiate reg function and enhance their survival at inflammatory sites.
